Atorvastatin ameliorates chronic subdural hematomas by interrupting the 'chronic subdural hematoma cycle' via inhibition of the inflammatory response.

ABSTRACT: Chronic subdural hematomas (CSDHs) are prevalent neurosurgical occurrences characterized by progressive hemorrhagic expansion, which is primarily mediated by persistent inflammation, angiogenesis and fibrinolytic dysregulation. Atorvastatin, a widely used lipid-lowering agent with known anti-inflammatory and angiogenesis-modulating properties, has shown therapeutic potential in CSDH management. In the present study, network pharmacology and experimental validation were combined to elucidate the underlying mechanisms of atorvastatin in CSDH treatment. Potential targets were identified through database mining and Venn analysis, followed by Gene Ontology/Kyoto Encyclopedia of Genes and Genomes enrichment, protein-protein interaction network construction and molecular docking. In vitro

SUBMITTER: Yan J 

PROVIDER: S-EPMC12683628 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature